{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:04:15Z","timestamp":1783699455260,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.urology.2020.11.008","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T11:20:41Z","timestamp":1605698441000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer"],"prefix":"10.1016","volume":"148","author":[{"given":"Amit S.","family":"Bhattu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Zappala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen J.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoj","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.11.008_bib0001","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2020.11.008_bib0002","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.juro.2018.06.016","article-title":"Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis","volume":"200","author":"Sathianathen","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0003","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","article-title":"Complications after prostate biopsy: data from SEER Medicare","volume":"186","author":"Loeb","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0004","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12894-018-0344-5","article-title":"Cost implications of PSA screening differ by age","volume":"18","author":"Rao","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0006","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.juro.2017.11.113","article-title":"A multi institutional prospective trial confirms noninvasive blood test maintains predictive valuein African American men","volume":"199","author":"Punnen","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2015.01.009","article-title":"Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of Kallikrein markers: a nested case-control study","volume":"68","author":"Stattin","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0008","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","article-title":"Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four Kallikrein markers in a large population-based cohort of healthy men","volume":"73","author":"Sjoberg","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0009","unstructured":"What are the patient restrictions for 4Kscore test? Available at: https:\/\/4kscore.com\/physician.html. Accessed on August 9, 2020."},{"key":"10.1016\/j.urology.2020.11.008_bib0010","unstructured":"National comprehensive cancer network (NCCN). Prostate cancer early detection, Version 2.2018 \u2014 April 5, 2018. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf. Accessed January 12, 2019."},{"key":"10.1016\/j.urology.2020.11.008_bib0011","series-title":"The Black Population: 2010. 2010 Census Briefs","author":"Rastogi","year":"2012"},{"key":"10.1016\/j.urology.2020.11.008_bib0012","first-page":"290","article-title":"Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2020.11.008_bib0013","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199608013350502","article-title":"Age-specific reference ranges for serum prostate-specific antigen in black men","volume":"335","author":"Morgan","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.11.008_bib0014","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.juro.2016.04.075","article-title":"Clinical use of PCA3 and TMPRSS2: ERG urinary biomarkers in African-American Men undergoing prostate biopsy","volume":"196","author":"Feibus","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.008_bib0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.urology.2015.12.004","article-title":"Prostate Health Index (PHI) predicts high-stage pathology in African American Men","volume":"90","author":"Schwen","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.11.008_bib0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euf.2015.12.005","article-title":"The 4Kscore predicts the grade and stage of prostate cancer in the radical prostatectomy specimen: results from a multi-institutional prospective trial","volume":"3","author":"Punnen","year":"2017","journal-title":"Eur Urol Focus"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520313716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520313716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:24:18Z","timestamp":1758767058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520313716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":16,"alternative-id":["S0090429520313716"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.11.008","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}